Medtronic has reported late-breaking data from the randomised Evolut Low Risk Trial’s five-year outcomes of the Evolut transcatheter aortic valve replacement (TAVR) system in low-risk aortic stenosis ...

Medtronic has released the two-year results from the clinical trial comparing its Evolut system to Edwards Lifesciences’ SAPIEN system. The Evolut system showed significantly less bioprosthetic ...

1,414 patients were randomized, with 730 receiving TAVR with either a Medtronic Evolut R, PRO, or CoreValve™ and 684 undergoing surgery. "Results at five years support Evolut's supra-annular ...

Medtronic (MDT) announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut transcatheter aortic valve replacement, TAVR, system ...

Patients with severe aortic stenosis had comparable rates of death or disabling stroke, but the lead investigator cautions against an 'irrational' rush to move to younger patients ahead of the data.

Medtronic, Abbott and Boston Scientific had updates on their devices used in heart valve disease treatment at the event.

The clinic data shows that Evolut TAVR continues to exhibit less bioprosthetic valve dysfunction compared to Edwards Lifesciences’ (EW) SAPIEN TAVR product. I think Medtronic has already made ...

GALWAY, Ireland and CHICAGO, March 30, 2025 /PRNewswire/ -- Medtronic plc (MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut ...

vice president and chief medical officer of Structural Heart, which is part of the Medtronic Cardiovascular Portfolio. "These results reinforce the recently reported Evolut evidence from the SMART ...